What's the Problem?
More than 18 million people are expected to die from infectious diseases and cancer by 2022. The reason is that we still don’t have effective vaccines or therapeutics for many diseases, for which the generation of antibodies is not enough. The solution will have to generate an effect called “cellular immune response”, that recognizes infected or tumoral cells to finally kill them.
How are they Solving it?
By using baculovirus (an insect virus safe for humans and animals), we developed a totally novel technology that is the only one designed to exploit the cellular immune response at its maximum capacity, enhancing this response 30,000 times compared to other solutions. For each disease, we use bioinformatics to choose some fragments of the pathogen or tumor. Next, we program the baculovirus by genetic engineering to send these fragments as a message to the immune system for the generation of an extraordinary cellular immune response. In the preclinical phase, the combination of our technology with a traditional vaccine against Chagas disease that had provided 30–40% of protection raised the efficacy to 92% of protection. Moreover, our technology is highly safe, and its production and storage are very simple and cheap: each dose costs only 25 cents for humans and much less for animals. We must be prepared for the next outbreaks, epidemics, and pandemics. Our platform will allow us to develop the next generation of vaccines in an incredibly easier and more effective way than ever before.